Top Markets
#1 Gravity Gravity +72.06%
#2 Galxe Galxe +41.65%
#3 Aria.AI Aria.AI +23.41%
#4 Velas Velas +22.90%
#5 Blast Blast +19.86%
#6 Magic Eden Magic Eden +19.09%
#7 Derive Derive +17.62%
#8 Codatta Codatta +16.35%
#9 Wrapped QUIL Wrapped QUIL +15.24%
#10 Pepe Pepe +14.83%
Coin of the day
Gravity Gravity
Settings
Language
ENGLISH
Currency
USD
Theme
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Rank in Stocks #157
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Share Price
$469.34
Market Cap
$119.21B
Change (1 day)
-1.84%
Change (1 year)
-7.87%
Country
US
Trade Vertex Pharmaceuticals Incorporated (VRTX)

Category

Healthcare
Market Capitalization
Revenue
more
Earnings
Price History
P/E Ratio
P/S Ratio
P/B Ratio
Operating Margin
EPS
Stock Splits
Dividends
Dividend Yield
Shares Outstanding
P/E ratio for Vertex Pharmaceuticals Incorporated (VRTX)
P/E ratio as of 2026 TTM: 0
According to Vertex Pharmaceuticals Incorporated latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Vertex Pharmaceuticals Incorporated from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.72 -
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 -
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 -
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 33.07 -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 38.30 -
NL
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.